BMS-986249

BMS-986249 is a conditionally activated, peptide-masked version of the anti–CTLA‑4 antibody ipilimumab. Developed using CytomX Therapeutics’ Probody technology and licensed to Bristol Myers Squibb, it is designed to be unmasked by tumor-associated proteases, thereby localizing its activity within the tumor microenvironment. This approach aims to minimize systemic toxicity and potentially allow for higher dosing compared to standard ipilimumab therapy. BMS‑986249 functions as an immune checkpoint inhibitor targeting cytotoxic T‑lymphocyte antigen 4 (CTLA‑4), enhancing T cell activation against cancer cells. It is being investigated primarily for advanced solid tumors and malignant melanoma, both as monotherapy and in combination with nivolumab[1][2][3][6].

Other names

anti–CTLA-4 probodyCTLA-4 ProbodyCTLA4 ProbodyCTLA 4 Probodyprobody anti-CTLA-4